Lab instruments may be leaking patient data, study finds

Healthcare IT News | February 26, 2019

The new report noted the cyber-physical nature of biotechnology workflows has created new security risks, which the research community has mostly neglected. The researchers, including Philip Brisk, a UC Riverside associate professor of computer science, and UC Irvine electrical and computer engineering professor Mohammad Abdullah Al Faruque, recommend labs using DNA synthesizing machines institute security measures. These include strictly controlling access to the machines and removing innocuous-seeming recording devices left nearby, including mobile devices like smartphones. “Any active machine emits a trace of some form: physical residue, electromagnetic radiation, acoustic noise, et cetera,” Brisk said in a statement. “The amount of information in these traces is immense, and we have only hit the tip of the iceberg in terms of what we can learn and reverse engineer about the machine that generated them.”

Spotlight

The Newport Hospital 2016 Summer Benefit, Casablanca, was a celebration of this special community hospital's many accomplishments while supporting it's most crucial funding needs. This video feature from the event demonstrates the important need for state-of-the-art ultrasound equipment in theWomen’s Health Services division of Newport Hospital. https://giving.lifespan.org/Casablanca


Other News
HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

FUTURE OF HEALTHCARE

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

GeneQuantum Healthcare | April 19, 2022

GeneQuantum Healthcare Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic antibody drug conjugate (ADC). Aimed Bio, a spin-off company from Samsung Medical Center, is focusing on developing innovative antibody-centric drugs for brain diseases with few treatment options. Additional details were not disclosed. GeneQuantum focuses on next generation Antibody Drug Conjugate development. Taking advantage of the proprietary 'Ligase Dependent Conjugation' technology platform, which allows a site-specific conjugation of cytotoxins or other type of payloads to antibodies, the company has successfully developed a robust pipeline with more than 10 assets, with several at or approaching clinical stage. In addition to expanding the unique technology platform, the company has entered into a number of partnerships with domestic biotech/pharmaceutical companies and international partners. The growing number of partnerships speaks to the power of the GeneQuantum platform technology for not only improving key therapeutic characteristics of existing molecules, but also for creating new classes of molecules, ultimately increasing the number of available treatment options for patients worldwide. GeneQuantum is excited about the significant potential of partnerships with business partners and will continue to expand its deal pipeline in the antibody drug conjugate and protein therapeutic market. The collaborating ADC is a first-in-class asset with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect. The resulting ADC is expected to treat brain and other cancers with huge unmet needs. "As an innovative antibody+ company, we look for complementary partners to maximize value of our platform technology. Aimed Bio not only has differentiated antibody acting on a unique target but also has deep knowledge and expertise in the field of brain tumor & CNS diseases. This collaboration is based on an excellent match between the two companies to generate a FIC ADC. Through close partnership, we are thrilled to bring revolutionary therapy for those patients without efficient treatment at this moment." Dr. Gang Qin, the Founder & Chairman, CEO of GeneQuantum Dr. Dohyun Nam, the Founder & Chairman, CTO of Aimed Bio and internationally renowned neurosurgeon with 32 years of experience in brain tumor & CNS diseases commented: "Aimed Bio has been successfully expanding its R&D pipeline for the past 2 years, and I am pleased to start this collaboration with GeneQuantum. After evaluating the data, the linker-payload and conjugation technology GeneQuantum provides proved to be very safe and effective. With the best antibody and brain tumor expertise of Aimed Bio, I believe the collaborating ADC will bring a tremendous impact on the field. We look forward to initiating clinical trial as soon as possible." About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutics. The company is focused on the development of a next generation of bioconjugate therapeutics to meet the unmet medical needs of cancer patients globally. For more information, visit www.genequantum.com. About AIMEDBIO Inc. AIMEDBIO is a spin-off company from Samsung Medical Center established in August 2018. AIMEDBIO aims to provide therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases, to save patients' lives and improve patients' quality of life. Based on solid global networks with key opinion leaders in the field, an excellent research team with profound achievements, and R&D pipelines with an outstanding drug development platform, AIMEDBIO is an emerging leader for development of innovative therapeutics against diverse brain diseases.

Read More

HEALTH TECHNOLOGY

Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health

Microba Life Sciences Limited | May 26, 2022

Microba Life Sciences Limited has signed a strategic partnership agreement with nib Holdings Limited backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market. Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based on their microbiome test results, leveraging the recommendations from Microba’s Analysis Platform. This personalised, pharmacy-integrated service model – delivered with trained, registered pharmacists – will bring a level of science and personalisation to an industry which commonly provides customers with one-size-fits-all solutions. Midnight Health CEO, Nic Blair said: “We are experiencing strong demand for innovative online healthcare solutions aligned to an individual needs. We already have more than 13,000 subscribers across our existing brands with strong month-on-month growth. Many of our customers are looking for gut health solutions and we are proud to bring the Vidality product to our customers in partnership with Microba”. The Agreement was signed, for an initial period of 3 years, after a successful pilot which tested the service model and product offering. It further demonstrates Microba’s scalable technology and ability to deliver evidence-based gut health solutions together with distribution partners. “Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology”. Microba CEO, Dr Luke Reid This delivers on an undertaking in the Company’s Prospectus to enter into an Australian partnership with a fast growth innovative consumer healthcare company. This announcement has been authorised for release by the Board. About Midnight Health Midnight Health delivers innovative online healthcare solutions through a patient-led digital platform. With the primary goal of democratising healthcare and enabling individuals to take control of their own healthcare, Midnight Health integrate telehealth technology, doctors, pharmacy network and other partners to provide a seamless patient experience for fast, convenient and discreet access to treatments, prescriptions and education through niche digital brand platforms. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Read More

FUTURE OF HEALTHCARE

TRC Healthcare Expands Portfolio with the Acquisition of QURE Healthcare

TRC Healthcare | March 16, 2022

TRC Healthcare a trusted leader in continuing education, has acquired QURE Healthcare, a recognized innovator in clinical measurement and quality improvement. QURE's provider-focused solutions lead to better patient outcomes and lower costs for healthcare systems and coverage and reimbursement for life-science clients. TRC's acquisition paves the way for QURE to scale its innovative Clinical Performance and Value (CPV®) patient simulation software solutions. "Through the acquisition, TRC Healthcare intends to augment its already robust suite of products by focusing on improving patient outcomes with evidence-based training, education and continuing education/continuing medical education for physicians and other providers" TRC Healthcare's CEO,Wes Crews, announced. "QURE is excited to join a company that is so aligned with our mission to raise the quality of healthcare, standardize practice and lower costs by changing clinician behavior. Measuring and reducing care variation using CPV®vignettes is QURE's core business. We have demonstrated in the peer-review literature that we can do this from the ambulatory to the intensive care setting and for diseases ranging from angina to zoonoses, all with the goal to eliminate unwarranted variation, raise quality for patients and lower costs for payers." Dr.John Peabody, the founder and president of QURE TRC Healthcare regards QURE as another key addition to its recent acquisition of NetCE, an industry leading continuing education platform that educates nurses, physicians, and mental health professionals. Together, QURE and NetCE fortify the evidence-based healthcare solutions TRC offers, "The addition of QURE increases our link between strong education and better patient outcomes," remarkedWes Crews. Dr. Peabody will continue to serve as QURE's President and will take on the additional role of Chief Medical Officer at TRC Healthcare. Dr. Peabody is a renowned international health care figure in clinical care quality and a professor at theUniversity of California, San FranciscoandLos Angeles. In 2012, John started QURE Healthcare. The QURE platform – CPV® vignettes – has grown and become a widely adopted standard for measuring clinical practice. QURE CPVs are used by organizations looking to engage their providers in clinical variation reduction efforts, including large health care systems, independent practice associations, public and private payers, governments, non-governmental associations, and intergovernmental organizations. Dr. Peabody has contributed more than 200 articles, books, and abstracts to the peer-review literature, served on blue ribbon committees, testified before congress and advised heads of state on a wide variety of subjects notably quality improvement and the economic benefits of standardizing practice in healthcare systems. "QURE is an extraordinary company, with a validated product and team and an incredibly passionate community of users," saidWes Crews. "Together we can transform the way we engage providers and change patient care." About TRC Healthcare TRC Healthcare (TRC) is a premier source of lifelong learning solutions for healthcare professionals. TRC is most recognized for their education and CE offerings within the highly-regarded Pharmacist's Letter, Prescriber's Letter, and Pharmacy Technician's Letter. TRC also offers Pharmacy Technicians University, the leading online training program for pharmacy technicians. The Natural Medicines database makes it easy for subscribers to find unbiased, evidenced-based research about alternative drug therapies. Through the acquisition of CriticalPoint, NetCE and Bula TRC Healthcare has been expanding its offerings. CriticalPoint increases patient safety through a variety of educational compounding offerings concentrating on USP 797, 800, and 795. NetCE is an industry-leading, continuing- education platform supporting multiple professions including nurses, physicians, and mental health. And Bula provides legal and regulatory advice to retail pharmacies. These additions give TRC Healthcare the industry's largest catalog of continuing education and advisory services, with thousands of courses trusted by healthcare professionals to provide accredited training that meets continuing education and licensing requirements. About QURE QURE Healthcare is a provider engagement company committed to improving the quality of clinical care. using its proprietary technology, CPV®(Clinical Performance and Value) vignettes. CPV®vignettes

Read More

Spotlight

The Newport Hospital 2016 Summer Benefit, Casablanca, was a celebration of this special community hospital's many accomplishments while supporting it's most crucial funding needs. This video feature from the event demonstrates the important need for state-of-the-art ultrasound equipment in theWomen’s Health Services division of Newport Hospital. https://giving.lifespan.org/Casablanca

Resources